Novartis AG (NVS) Stock

Novartis AG is a renowned Swiss-based healthcare company at the forefront of researching, developing, manufacturing, and globally marketing a diverse array of healthcare products. Operating through two principal segments, Innovative Medicines and Sandoz, the company offers a comprehensive portfolio of prescription medicines catering to various therapeutic areas. These include cardiovascular health, ophthalmology, neuroscience, immunology, hematology, and treatments for solid tumors, addressing critical medical needs for patients and healthcare providers worldwide.

Within its Innovative Medicines segment, Novartis focuses on delivering innovative therapies that advance medical science and improve patient outcomes. This segment remains pivotal in driving the company's commitment to cutting-edge research and development across multiple disease areas. Meanwhile, the Sandoz segment specializes in the development, manufacturing, and distribution of finished dosage forms of small molecule pharmaceuticals and biotechnology-based products. This includes biosimilars and biotechnology manufacturing services, reinforcing Novartis's dedication to expanding access to high-quality, affordable healthcare solutions.

Established in 1996 and headquartered in Basel, Switzerland, Novartis AG has built a reputation for excellence in healthcare innovation. The company continues to lead through strategic collaborations, such as its partnership with Alnylam Pharmaceuticals to develop inclisiran, a groundbreaking therapy aimed at reducing LDL cholesterol levels. With a steadfast commitment to scientific rigor and patient-centric innovation, Novartis AG remains committed to shaping the future of medicine and improving global health outcomes.